Innate Pharma S.A. (FR:IPH) has released an update.
Innate Pharma S.A. has presented promising preclinical data for its anti-Nectin-4 Antibody Drug Conjugate, IPH45, and is advancing multiple drug candidates, including the Phase 2 SAR443579/IPH6101 for blood cancers developed with Sanofi. The company maintains a solid cash position of €113.9 million, expecting to sustain operations into late 2025, and is preparing to showcase several studies at the upcoming ASCO Annual Meeting 2024.
For further insights into FR:IPH stock, check out TipRanks’ Stock Analysis page.
